TARS FY 2023 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M-32.4% YoY

Gross Profit

$16M90.9% margin

Operating Income

-$143M-820.5% margin

Net Income

-$136M-778.9% margin

EPS (Diluted)

$-4.62

Cash Flow

Operating Cash Flow

-$117M

Free Cash Flow

-$123M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$265M

Total Liabilities

$69M

Stockholders' Equity

$197M

Cash & Equivalents

$225M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$26M	-32.4%
Gross Profit	$16M	$25M	-36.2%
Operating Income	-$143M	-$63M	-128.3%
Net Income	-$136M	-$62M	-118.9%